Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GENETICS INSTITUTE'S ERYTHROPOIETIN PURIFICATION TECHNIQUE

Executive Summary

GENETICS INSTITUTE'S ERYTHROPOIETIN PURIFICATION TECHNIQUE is one of three specific claims covered under a patent granted to the firm on June 30. The patent claims: "A method for purifying human erythropoietin comprising treating partially purified erthropoietin having a specific activity of at least about 80,000 IU per absorbance unit at 280 nanometers by reverse phase high performance liquid chromatography and eluting therefrom homogeneous human erythropoietin which moves as a single peak on reverse phase high performance liquid chromatography and is characterized by a specific activity of at least 160,000 IU per absorbance unit at 280 nanometers." "Patent claims on the actual substance cover a homogeneous erythropoietin characterized by a molecular weight of about 34,000 daltons on SDS PAGE, movement as a single peak on reverse phase high performance liquid chromatography and a specific activity of at least 160,000 IU per absorbance unit at 280 nanometers." In addition to the protein and purification process, the patent also covers the resulting pharmaceutical product. The product claim is for "a pharmaceutical composition for the treatment of anemia comprising a therapeutically effective amount of the homogenous erythropoietin [covered by the patent] in a pharmaceutically acceptable vehicle." The patent states that the purification technique used by Genetics Institute improves upon currently used purification procedures. The patent explains that current purification steps "include ethanol precipitation, DEAE-agarose fractionation, sulfopropyl-Sephadex chromatography, gel filtration and hydroxylapatite chromatography." The patent states that "the present invention . . . further [purifies erythropoietin] by reverse phase high performance liquid chromatography to obtain a homogeneous EPO [erythropoietin] protein." Purified EPO compositions produced by those techniques, the patent states, have "been found to be non-homogenous." The patent notes that "no matter what the source of EPO is [ie. natural or recombinant], the EPO protein must be purified to homogeneity for therapeutic use." In a July 1 release announcing the patent, Genetics Institute said it believes "that our patent claims cover all erythropoietin products currently undergoing clinical trials, both by licensees of Genetics Institute as well as unlicensed competitors." Genetics Institute licenses its EPO to the Japanes firm Chugai, which is currently conducting trials in Japan and plans to begin U.S. trials "shortly," the release states. Amgen, furthest along in the clinical development of EPO, is in Phase II trials with its recombinant product in kidney dialysis patients. Amgen has licensed EPO rights in Japan to Kirin and in the rest of the world, excluding China, to J&J. J&J also has rights to the non-dialysis anemia market for EPO in the U.S. Both Amgen and Genetics Institute have patents pending for a genetically engineered process for producing EPO.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS012122

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel